Back to Results
First PageMeta Content
Clinical pharmacology / Food and Drug Administration / Pharmacology / Therapeutics / United States Public Health Service / Icaria / Approved drug / Pharmaceutical sciences / Research / Clinical research


IKARIA® NAMES NEW HEAD OF RESEARCH & DEVELOPMENT Clinton, NJ, June 1, 2010 – Ikaria, Inc. today announced that Douglas Greene, M.D., has been appointed Executive Vice President of Research and Development (R&D). In th
Add to Reading List

Document Date: 2011-06-28 11:52:59

Open Document

File Size: 57,15 KB

Share Result on Facebook

City

Madison / Seattle / Port Allen / /

Company

Sanofi / Ikaria Inc. / /

Country

Puerto Rico / Japan / United States / Canada / Australia / Mexico / /

Event

Employment Change / M&A / FDA Phase / /

IndustryTerm

manufacturing facility / pharmaceutical industry / drug product / treatment of hypoxic respiratory failure / treatment for hepatorenal syndrome / /

MedicalCondition

pulmonary hypertension / subsequent congestive heart failure / hypoxic respiratory failure / acute myocardial infarction / /

Organization

US Food and Drug Administration / Endocrinologic and Metabolic Drug Advisory Committee / Advisory Committee / /

Person

Ralf Rosskamp / Douglas Greene / Daniel Tassé / Clinton / Doug / /

Position

leader / Chairman / HEAD OF RESEARCH & DEVELOPMENT / Chief Medical Officer of the US business / Chairman and CEO / Executive Vice President / Executive Vice President of Research and Development / Vice President of R&D / member / /

Product

INOMAX / INOtherapy® / /

ProvinceOrState

Wisconsin / Louisiana / Washington / /

URL

www.ikaria.com / /

SocialTag